雷速体育_中国足彩网￥在线直播 雷速体育_中国足彩网￥在线直播

Acetylcholine is a neurotransmitter in the brain that plays an important role in controlling attention and cognition. Acetylcholine system dysfunction is believed to be one of the causes of Alzheimer's disease (AD) and vascular dementia.

Now, a new drug that could treat Alzheimer's disease, SAK3, has been developed by a Japanese research group led by Tohoku University Professor Kohji Fukunaga.

In their study, the researchers found that the T-type calcium channel enhancer, SAK3, stimulates the release of acetylcholine in the brain and improves cognition by activating the memory molecule CaMKII. According to Professor Fukunaga, SAK3 also reduces the production of amyloid beta protein in the study's model mice. This, he says, could lead to the development of the first disease-modifying drug to prevent mild to severe Alzheimer disease.

SAK3 is now in the preclinical stage of drug development, and has so far proven to be safe and well-tolerated in animal experiments. Clinical trials are expected to begin in the next few years.

This research is partially supported by the Japan 雷速体育_中国足彩网￥在线直播ncy for Medical 雷速体育_中国足彩网￥在线直播 and Development's Project of Translational and Clinical 雷速体育_中国足彩网￥在线直播 Core Center.

Discovery of SAK3 to enhance T-type calcium channels in nerve terminals

Publication Details:

Title: Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer.
Authors: Yasushi Yabuki, Kazuya Matsuo, Hisanao Izumi, Hidaka Haga, Takashi Yoshida, Minoru Wakamori, Akikazu Kakei, Kenji Sakimura, Takaichi Fukuda and Kohji Fukunaga
Journal: Neuropharmacology
DOI:10.1016/j.neuropharm.2017.01.011